Evidence
Acta Neuropathol. 2022 Sep 6. doi: 10.1007/s00401-022-02454-z. Online ahead of print.
ABSTRACT
Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer’s disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dementia Biobank (EADB), the largest collaborative effort on genetics underlying CSF biomarkers was established, including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals). Besides the APOE locus, novel associations with two other well-established AD risk loci were observed; CR1 was shown a locus for Aβ42 and BIN1 for pTau. GMNC and C16orf95 were further identified as loci for pTau, of which the latter is novel. Clustering methods exploring the influence of all known AD risk loci on the CSF protein levels, revealed 4 biological categories suggesting multiple Aβ42 and pTau related biological pathways involved in the etiology of AD. In functional follow-up analyses, GMNC and C16orf95 both associated with lateral ventricular volume, implying an overlap in genetic etiology for tau levels and brain ventricular volume.
PMID:36066633 | DOI:10.1007/s00401-022-02454-z
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly
- Associations of CSF BACE1 with amyloid pathology, neurodegeneration, and cognition in Alzheimer's disease
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias
- Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Biomarkers of neurodegeneration in schizophrenia: systematic review and meta-analysis
- Cerebrospinal fluid a-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults
- Alzheimer-Type Cerebral Amyloidosis in the Context of HIV Infection: Implications for a Proposed New Treatment Approach
- The influence of APOEε4 on the pTau interactome in sporadic Alzheimer's disease
- Cerebrospinal fluid amyloid-β and cerebral microbleed are associated with distinct neuropsychiatric sub-syndromes in cognitively impaired patients
- Echocardiographic measures of the left heart and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study
- Potential Biomarkers in Cerebrospinal Fluid and Plasma for Dementia
- Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study
- Physical activity may a probably protective factor for postoperative delirium: the PNDABLE study
- Longitudinal trajectories of Alzheimer's disease CSF biomarkers and blood pressure in cognitively healthy subjects
- Towards cascading genetic risk in Alzheimer's disease
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies
- Cerebrospinal fluid synaptic biomarker changes in bipolar disorder - A longitudinal case-control study
- A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function
- Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies
- Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application
- Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population
- Abnormal EEG microstates in Alzheimer's disease: predictors of b-amyloid deposition degree and disease classification
- Adaptive immune changes associate with clinical progression of Alzheimer's disease
- The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy
- Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer's disease
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease
- Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly
- Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology
- Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia
- Genome-wide analyses reveal a potential role for the MAPT, MOBP, and APOE loci in sporadic frontotemporal dementia
- a-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden
- Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer's disease
- The genetic architecture of dog ownership: large-scale genome-wide association study in 97,552 European-ancestry individuals
- Blood Pressure Variability and Plasma Biomarkers of Neuronal Injury and Alzheimer's Disease: A Clinic-Based Study of Patients with Diseases Along the Heart-Brain Axis
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Association of symptom severity and cerebrospinal fluid alterations in recent onset psychosis in schizophrenia-spectrum disorders - An individual patient data meta-analysis
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Alteration of gene expression and protein solubility of the PI 5-phosphatase SHIP2 are correlated with Alzheimer's disease pathology progression
- Alteration of gene expression and protein solubility of the PI 5-phosphatase SHIP2 are correlated with Alzheimer's disease pathology progression
- Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting
- Biomarkers of Neurodegeneration and Alzheimer's Disease Neuropathology in Adolescents and Young Adults with Youth-Onset Type 1 or Type 2 Diabetes: A Proof-of-Concept Study
- Association analyses of apolipoprotein E genotypes and cognitive performance in patients with Parkinson's disease
- Early and selective localization of tau filaments to glutamatergic subcellular domains within the human anterodorsal thalamus
- Ubiquity of Synthetic Phenolic Antioxidants in Children's Cerebrospinal Fluid from South China: First Evidence for Their Penetration across the Blood-Cerebrospinal Fluid Barrier
- Choriocapillaris reduction accurately discriminates against early-onset Alzheimer's disease
- Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease
- Total Tau Protein Mediates the Association of Ischemic Cerebrovascular Disease with Cognitive Decline
- Onset of Alzheimer disease in apolipoprotein ɛ4 carriers is earlier in butyrylcholinesterase K variant carriers
- Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy
- Disentangling and quantifying the relative cognitive impact of concurrent mixed neurodegenerative pathologies
- Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort
- Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis
- Protocol to characterize immune cell subpopulations in cerebrospinal fluid of patients with neuroinflammatory diseases using mass cytometry
- Protocol to characterize immune cell subpopulations in cerebrospinal fluid of patients with neuroinflammatory diseases using mass cytometry
- Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
- Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy
Evidence Blueprint
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3
- CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly
- CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer's disease
- CRISPR-Powered Aptasensor for Diagnostics of Alzheimer's Disease
- Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease
- Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms
- Associations of CSF BACE1 with amyloid pathology, neurodegeneration, and cognition in Alzheimer's disease
- Associations between cardiometabolic multimorbidity and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study
- A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias
- Cerebrospinal fluid neutral lipids predict progression from mild cognitive impairment to Alzheimer's disease
- Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology
- Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer's disease neuropathology at autopsy
- Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics
- CSF metabolites associated with biomarkers of Alzheimer's disease pathology
- Use of modern classification systems for complex diagnostics of Alzheimer's disease
- Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts
- High burdens of phosphorylated tau protein and distinct precuneus atrophy in sporadic early-onset Alzheimer's disease
- Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case-control study of patients with bipolar disorder and healthy control individuals
- APOE-ε4 and BIN1 increase risk of Alzheimer's disease pathology but not specifically of Lewy body pathology
- Association of CSF biomarkers with MRI brain changes in Alzheimer's disease
- Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Harmonization of CSF and imaging biomarkers for Alzheimer's disease: Need and practical applications for genetics studies and preclinical classification
- Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression
- Associations between liver function and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in non-demented adults: The CABLE study
- Diagnostic utility of cerebrospinal fluid biomarkers in patients with rapidly progressive dementia
- Biomarkers of neurodegeneration in schizophrenia: systematic review and meta-analysis
- Biomarkers of Alzheimer's disease and cerebrovascular disease in relation to depressive symptomatology in individuals with subjective cognitive decline
- Differential Associations of APOEɛ2 and APOEɛ4 Genotypes with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease in Individuals Without Dementia
- Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings
- Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains
- The Association of Alzheimer's Disease-Related Blood-Based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa
- Cerebrospinal fluid a-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults
- Alzheimer-Type Cerebral Amyloidosis in the Context of HIV Infection: Implications for a Proposed New Treatment Approach
- Prevalence and Clinical Implications of a β-Amyloid-Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease
- Plasma and cerebrospinal fluid nonenzymatic protein damage is sustained in Alzheimer's disease
- The influence of APOEε4 on the pTau interactome in sporadic Alzheimer's disease
- Cerebrospinal fluid amyloid-β and cerebral microbleed are associated with distinct neuropsychiatric sub-syndromes in cognitively impaired patients
- The Relationship of Cerebrospinal Fluid Biomarkers and Cognitive Performance in Frontotemporal Dementia
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
- Associations of cerebrospinal fluid complement proteins with Alzheimer's pathology, cognition, and brain structure in non-dementia elderly
- Echocardiographic measures of the left heart and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study
- Potential Biomarkers in Cerebrospinal Fluid and Plasma for Dementia
- CSF protein ratios with enhanced potential to reflect Alzheimer's disease pathology and neurodegeneration
- Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer's Disease
- Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study
- Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO
- Effect of Pathway-Specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-Related Biomarkers Among Asymptomatic Individuals
- Physical activity may a probably protective factor for postoperative delirium: the PNDABLE study
- CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease
- Longitudinal trajectories of Alzheimer's disease CSF biomarkers and blood pressure in cognitively healthy subjects
- Towards cascading genetic risk in Alzheimer's disease
- APOE - ε 4 and BIN1 increase risk of Alzheimer's disease pathology but not specifically of Lewy body pathology
- Multiancestry analysis of the HLA locus in Alzheimer's and Parkinson's diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- White matter hyperintensity volume modifies the association between CSF vascular inflammatory biomarkers and regional FDG-PET along the Alzheimer's disease continuum
- Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies
- Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases
- Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings
- Cerebrospinal fluid synaptic biomarker changes in bipolar disorder - A longitudinal case-control study